Skip to main content

Table 2 Response and clinical benefit by risk category for all patients (n = 810)

From: Overall survival by clinical risk category for high dose interleukin-2 (HD IL-2) treated patients with metastatic renal cell cancer (mRCC): data from the PROCLAIMSM registry

Best response Favorable (n = 249) Intermediate (n = 480) Poor risk (n = 81)
CR 9 (3.6%) 34 (7%) 1 (1.2%)
PR 52 (21%) 91 (19%) 13 (16%)
SD 128 (51.4%) 185 (38.5%) 24 (30%)
PD 48 (19%) 135 (28%) 34 (42%)
Missing 12 (5%) 35 (7.3%) 9 (11%)
CR + PR 61 (24.5%) 125 (26%) 14 (17.3%)
CR + PR + SD 189 (75.9%) 310 (64.6%) 38 (46.9%)
  1. CR complete response, PR partial response, SD stable disease, PD progressive disease